Paulo Reis MD MBA
Vice President - Global Patient Safety - Immunology
Indianapolis, Indiana, United States · 1 connectionNot on Unlinked · Imported profile. Is this you? Claim it
Is this about you? Request removal
About
Physician-executive with 25+ years operating across clinical medicine, regulatory science, and pharmaceutical leadership. Currently VP, Global Patient Safety — Immunology at Eli Lilly, with a career spanning Medical Affairs, Clinical Development, and Drug Safety across Rheumatology, Gastroenterology, and Immunology. At Lilly, I have led Global and US Medical Affairs for a portfolio of major immunology assets — including the launches of Taltz (Psoriasis, PsA, AS, nr-axSpA) and Olumiant (RA) — and directed Medical Affairs strategy and execution across three therapeutic areas simultaneously. I have built and led large cross-functional teams, driven the transformation of the Medical Affairs function within a major business unit, and most recently taken accountability for global patient safety in Immunology. Earlier in my career, I served as Head of Division of Medicines for Human Use at INFARMED (the Portuguese Medicines Agency), representing Portugal at the EMA's CHMP and multiple scientific working groups — giving me a regulatory perspective few Medical Affairs or Safety leaders possess. I also hold an MBA and spent over a decade as a Business Unit Director with full P&L responsibili
Experience
Jun 2023 to Dec 2025
Mar 2023 to Jun 2023
Mar 2022 to Feb 2023
Dec 2021 to Mar 2022
Mar 2021 to Dec 2021
Jun 2020 to Mar 2021
Apr 2018 to Jun 2020
Sep 2017 to Apr 2018
Feb 2017 to Aug 2017
Dec 2016 to Feb 2017
May 1998 to Mar 2005
Jan 1998 to Feb 2003
Education
Master of Business Administration (MBA), Management, Marketing
2008 to 2010
Master of Business Administration (M.B.A.), Business Administration and Management, General
2003 to 2004
Consultant, Rheumatology
1998 to 2006
Doctor of Medicine (MD), Medicine
1981 to 1987
Rheumatologist, Medicine
1996
Doctor of Medicine - MD, Rheumatology Residency Program
1991 to 1998